These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16413338)

  • 1. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia.
    Slawin KM; Kattan MW; Roehrborn CG; Wilson T
    Urology; 2006 Jan; 67(1):84-8. PubMed ID: 16413338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM; Runken MC; Grogg AL; Shah MB
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
    Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
    Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
    Fenter TC; Davis EA; Shah MB; Lin PJ
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
    Roeloffzen EM; van Vulpen M; Battermann JJ; van Roermund JG; Saibishkumar EP; Monninkhof EM
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):737-44. PubMed ID: 20888131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
    Roehrborn CG; Lukkarinen O; Mark S; Siami P; Ramsdell J; Zinner N
    BJU Int; 2005 Sep; 96(4):572-7. PubMed ID: 16104912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial).
    Bepple JL; Barone BB; Eure G
    Urology; 2009 Nov; 74(5):1101-4. PubMed ID: 19800668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.